A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation.
Yfanti C, Vestbjerg B, Van't Westende J, Edvardsson N, Monfort LM, Olesen MS, Bentzen BH, Grunnet M, Eveleens Maarse BC, Diness JG, Kemme MJB, Sørensen U, Moerland M, van Esdonk MJ, Klaassen ES, Gal P, Holst AG.
Yfanti C, et al. Among authors: eveleens maarse bc.
Br J Clin Pharmacol. 2024 Apr;90(4):1027-1035. doi: 10.1111/bcp.15973. Epub 2024 Jan 8.
Br J Clin Pharmacol. 2024.
PMID: 37990600
Clinical Trial.